Apellis Pharmaceuticals Announces That APL-2 Met Its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-...
August 24, 2017
MaxCyte, Inc. - First Day of Dealings on AIM
March 30, 2016
Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
November 8, 2017
MaxCyte Presents Unprecedented CHO-Based Transient Gene Expression Data for Gram Scale Antibody Production and Rapid Stable Cell Line Generation at CHI's 2013 Protein and Antibody Engineering Summit
April 27, 2013
First Transient Gene Expression (TGE) Method Reporting Over 1 gram/liter Antibody Titers
Gaithersburg, Maryland - MaxCyte, Inc., the pioneer in scalable, high performance cell transfection systems, is hosting a series of events at Cambridge Health Institutes PEGS Summit, the premier conference in the protein and antibody biotherapeutic arena, being held April 29 May 3 in Boston, MA. During the conference, MaxCyte will present break-through transient gene expression (TGE) data in a scientific podium presentation and detail unmatched antibody production capabilities in two technical posters. MaxCyte scientists will be available throughout the conference at Booth #216 to provide further technical details about the use of flow electroporation for large scale transient gene expression and rapid stable cell line generation.
Dr. James Brady, Director of Technical Applications at MaxCyte, will present data on flow electroporation in a podium presentation entitled Streamlining Antibody Development Using Large Scale, CHO Transient Gene Expression (TGE) followed by Rapid Production of CHO Stable Clones on Wednesday, May 1, at 3:05 PM within a session dedicated to discussing protein expression in CHO cells, the standard manufacturing cell line for bioproduction.-
"Dr. Bradys presentation demonstrates the unmatched performance of the MaxCyte Scalable Transfection Systems," says Dr. Karen Donato, Executive Vice President of Global Business Development & Marketing at MaxCyte. "No other transient transfection system has the capabilities of MaxCyte electroporation, namely CHO-based expression with antibody titers of over 1 gram/liter, combined with the rapid creation of high yield stable cell lines."
MaxCyte will also present two scientific posters, both available for viewing on Thursday, May 2nd, from 3:10 PM - 4:00 PM and Friday, May 3rd, from 10:05 AM - 10:50 AM. The first poster, entitled "CHO Transient Gene Expression (TGE) Optimization for Multi-Gram Level Antibody Production: Effects of Expression Construct, Post Transfection Cell Density and Feed Conditions" highlights the transfection and post transfection flexibility of flow electroporation which allows for the full optimization of antibody expression producing antibody titers that can exceed 1 gram/liter within 14 days of transfection. This poster is presented in collaboration with Vivalis, a key client and leading provider of innovative cellbased solutions to the pharmaceutical industry for the manufacture of vaccines and recombinant proteins.
The second poster, entitled "Bioproduction Using Large Scale Transient Transfection: From >1.2 grams/L Antibody Titers via Transient Gene Expression (TGE) to Rapid, High Yield Stable Cell Line Generation", summarizes data demonstrating the utility of the MaxCyte platform at multiple steps in antibody development including high yield antibody production via transient gene expression and rapid generation of stable cell lines in 6-8 weeks for late stage development and biomanufacturing.
"Our clients have already realized the benefits of streamlining progression from early to late stage development by using our one-of-a-kind technology that brings together transient gene expression and rapid stable cell generation," says Douglas Doerfler, President, and CEO of MaxCyte. "MaxCyte flow electroporation is a truly enabling technology and we look forward to presenting our latest scientific findings to leaders in the development of biotherapeutics at the PEGS Summit."